RE: Judging ManagementYes good move because they knew that they would need to stop enrollment in GBM trial, because it was not going as hoped. This is probably why Falardeau left at the same time. They needed that extra money to probably start a new trial with 4601. Good management move, but likely to come with bad news for actual shareholders. The bad news being new delays and continuing uncertainty while burning this new cash on their only valid candidate. All that is now worth 0.095$ a share.